Ineffectiveness of tigecycline against persistent Borrelia burgdorferi

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 2, 2010, Pages 643-651

  Barthold, Stephen W ^a   Hodzic, Emir ^a   Imai, Denise M ^a   Feng, Sunlian ^a   Yang, Xiaohua ^b   Luft, Benjamin J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CEFTRIAXONE; DOXYCYCLINE; PENICILLIN G; TIGECYCLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL VIABILITY; BACTERIUM CULTURE; BORRELIA BURGDORFERI; C3H MOUSE; CONTROLLED STUDY; DISEASE COURSE; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HEART; JOINT; LOW DRUG DOSE; LYME DISEASE; MOLTING; MOUSE; NONHUMAN; NYMPH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; SCID MOUSE; SURVIVAL RATE; TICK BITE; TISSUE TRANSPLANTATION; TREATMENT DURATION; XENODIAGNOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIGENS, SURFACE; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; CEFTRIAXONE; FEMALE; LIPOPROTEINS; LYME DISEASE; MICE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; POLYMERASE CHAIN REACTION; TICKS;

EID: 75749107000     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00788-09     Document Type: Article

References (82)

1. Appel, M. J. G., S. Allan, R. H. Jacobson, T. L. Lauderdale, Y. F. Chang, S. J. Shin, J. W. Thomford, R. J. Todhunter, and B. A. Summers. 1993. Experimental Lyme disease in dogs produces arthritis and persistent infection. J. Infect. Dis. 167:651-664.
2. Armstrong, A. L., S. W. Barthold, D. H. Persing, and D. S. Beck. 1992. Carditis in Lyme disease susceptible and resistant strains of laboratory mice infected with Borrelia burgdorferi. Am. J. Trop. Med. Hyg. 47:249-258.
3. Asbrink, E., and A. Hovmark. 1985. Successful cultivation of spirochetes from skin lesions of patients with erythema chronica migrans afzelius and acrodermatitis chonica atrophicans. Acta Pathol. Microbiol. Immunol. Scand. 93:161-163.
4. Balaban, N. Q., J. Merrin, R. Chait, L. Kowalik, and S. Leibler. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622- 1625.
5. Barbour, A. G. 1984. Isolation and cultivation of Lyme disease spirochetes. Yale J. Biol. Med. 57:521-525.
6. Barthold, S. W. 1993. Antigenic stability of Borrelia burgdorferi during chronic infections of immunocompetent mice. Infect. Immun. 61:4955-4961.
7. Barthold, S. W., M. S. deSouza, J. L. Janotka, A. L. Smith, and D. H. Persing. 1993. Chronic Lyme borreliosis in the laboratory mouse. Am. J. Pathol. 143:951-971.
8. Barthold, S. W., E. Fikrig, L. K. Bockenstedt, and D. H. Persing. 1995. Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi. Infect. Immun. 63:2255-2261.
9. Barthold, S. W., D. H. Persing, A. L. Armstrong, and R. A. Peeples. 1991. Kinetics of Borrelia burgdorferi dissemination and evolution of disease following intradermal inoculation of mice. Am. J. Pathol. 139:263-273.
10. Barthold, S. W., C. L. Sidman, and A. L. Smith. 1992. Lyme borreliosis in genetically resistant and susceptible mice with severe combined immunode-ficiency. Am. J. Trop. Med. Hyg. 47:605-613.
11. Bigger, J. W. 1944. Treatment of staphylococcal infections with penicillin by intermittent sterilization. Lancet ii:497-500.
12. Blaser, M. J., and D. Kirschner. 2007. The equilibria that allow bacterial persistence in human hosts. Nature 449:843-849.
13. Bockenstedt, L. K., J. Mao, E. Hodzic, S. W. Barthold, and D. Fish. 2002. Detection of attenuated, non-infectious spirochetes after antibiotic treatment of Borrelia burgdorferi-infected mice. J. Infect. Dis. 186:1430-1437.
14. Bradley, J. F., R. C. Johnson, and J. L. Goodman. 1994. The persistence of spirochetal nucleic acids in active Lyme arthritis. Ann. Intern. Med. 120: 487-489.
15. Bunikis, I., K. Denker, Y. Ostberg, C. Andersen, R. Benz, and S. Bergstrom. 2008. An RND-type efflux system in Borrelia burgdorferi is involved in virulence and resistance to antimicrobial compounds. PLoS Pathog. 4:e1000009.
16. Chang, Y. F., R. K. Straubinger, R. H. Jacobson, J. B. Kim, D. Kim, S. J. Shin, and M. J. G. Appel. 1996. Dissemination of Borrelia burgdorferi after experimental infection in dogs. J. Spirochetal Tick Borne Dis. 3:80-86.
17. Embers, M. E., F. T. Liang, J. K. Howell, M. B. Jacobs, J. E. Purcell, S. J. Norris, B. J. B. Johnson, and M. T. Philipp. 2007. Antigenicity and recombination of VlsE, the antigenic variation protein of Borrelia burgdorferi, in rabbits, a host putatively resistant to long-term infection with this spirochete. FEMS Immunol. Med. Microbiol. 50:421-429.
18. Feng, S., E. Hodzic, B. Stevenson, and S. W. Barthold. 1998. Humoral immunity to Borrelia burgdorferi N40 decorin binding proteins during infection of laboratory mice. Infect. Immun. 66:2827-2835.
19. Frazer, D. D., L. I. King, and F. W. Miller. 1992. Molecular detection of persistent Borrelia burgdorferi in a man with dermatomyositis. Clin. Exp. Rheumatol. 10:387-390.
20. Goodman, J. L., P. Jurkovich, C. Kodner, and R. C. Johnson. 1991. Persistent cardiac and urinary tract infections with Borrelia burgdorferi in experimentally infected Syrian hamsters. J. Clin. Microbiol. 29:894-896.
21. Greer, N. D. 2006. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc. Baylor Univ. Med. Center 19:155-161.
22. Hassler, D., L. Zoller, M. Haude, H. D. Hufnagel, F. Heinrich, and H. G. Sonntag. 1990. Cefotaxime versus penicillin in the late stage of Lyme disease - a prospective, randomized therapeutic study. Infection 18:16-20.
23. Haupl, T., G. Hahn, M. Rittig, A. Krause, C. Schoerner, U. Schonherr, J. R. Kalden, and G. R. Burmester. 1993. Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum. 36:1621-1626.
24. Hefty, P. S., C. S. Brooks, A. M. Jett, G. L. White, S. K. Wikel, R. C. Kennedy, and D. R. Akins. 2002. OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human Lyme disease patients. J. Clin. Microbiol. 40:4256-4265.
25. Hodzic, E., S. Feng, K. Freet, and S. W. Barthold. 2003. Borrelia burgdorferi population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. Infect. Immun. 71:5042-5055.
26. Hodzic, E., S. Feng, K. J. Freet, D. L. Borjesson, and S. W. Barthold. 2002. Borrelia burgdorferi population kinetics and selected gene expression at the host-vector interface. Infect. Immun. 70:3382-3388.
27. Hodzic, E., S. Feng, K. Holden, K. J. Freet, and S. W. Barthold. 2008. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52:1728-1736.
28. Hudson, B. J., M. Stewart, V. A. Lennox, M. Fukunaga, M. Yabuki, H. Macorison, and J. Kitchener-Smith. 1998. Culture-positive Lyme borreliosis. Med. J. Aust. 168:500-502.
29. Hunfeld, K. P., E. Ruzic-Sablic, D. E. Norris, P. Kraiczy, and F. Strle. 2005. In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial therapy. Antimicrob. Agents Chemother. 49:1294-1301.
30. Jayaraman, R. 2008. Bacterial persistence: some new insights into an old phenomenon. J. Biosci. 33:795-805.
31. Johnson, R. C., C. Kodner, and M. Russell. 1987. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob. Agents Chemother. 31:164-167.
32. Johnson, R. C., C. Kodner, M. Russell, and P. H. Duray. 1988. Experimental infection of hamsters with Borrelia burgdorferi. Ann. N. Y. Acad. Sci. 539: 258-263.
33. Johnson, R. C., C. B. Kodner, P. J. Jurkovich, and J. J. Collins. 1990. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to defuroxime and other antimicrobial agents. Antimicrob. Agents Chemother. 34:2133-2136.
34. Kazragis, R. J., L. L. Dever, J. H. Jorgensen, and A. G. Barbour. 1996. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob. Agents Chemother. 40:2632-2636.
35. Koomanachai, P., A. Kim, and D. P. Nicolau. 2009. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J. Antimicrob. Chemother. 63:982-987.
36. Kuiper, H., A. P. van Dam, L. Spanjaard, B. M. deJongh, A. Widjojokusumo, T. C. P. Ramselaar, I. Cairo, K. Vos, and J. Dankert. 1994. Isolation of Borrelia burgdorferi from biopsy specimens taken from healthy-looking skin of patients with Lyme borreliosis. J. Clin. Microbiol. 32:715-720.
37. Levin, B. R., and D. E. Rozen. 2006. Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4:556-562.
38. Lewis, K. 2008. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol. 322:107-131.
39. Lewis, K. 2007. Persister cells, dormancy and infectious disease. Nat. Rev. Microbiol. 5:48-56.
40. Luft, B. J., D. J. Volkman, J. J. Halperin, and R. J. Dattwyler. 1988. New chemotherapeutic approaches in the treatment of Lyme borreliosis. Ann. N. Y. Acad. Sci. 539:352-361.
41. Malawista, S. M., S. W. Barthold, and D. H. Persing. 1994. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J. Infect. Dis. 170:1312-1316.
42. Medrano, M. S., Y. Ding, X. G. Wang, P. Lu, and L. T. Hu. 2007. Regulators of expression of the oligopeptide permease A proteins of Borrelia burgdorferi. J. Bacteriol. 189:2653-2659.
43. Miklossy, J., K. Khalli, L. Gern, R. L. Ericson, P. Darekar, L. Bolle, J. Hurlimann, and B. J. Paster. 2004. Borrelia burgdorferi persists in the brain in chronic Lyme neuroborreliosis and may be associated with Alzheimers disease. J. Alzheimers Dis. 6:639-649.
44. Moody, K. D., R. L. Adams, and S. W. Barthold. 1994. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob. Agents Chemother. 38:1567-1572.
45. Moody, K. D., S. W. Barthold, G. A. Terwilliger, D. S. Beck, G. M. Hansen, and R. O. Jacoby. 1990. Experimental chronic Lyme borreliosis in Lewis rats. Am. J. Trop. Med. Hyg. 42:65-74.
46. Moter, S. E., H. Hofmann, R. Wallich, M. M. Simon, and M. D. Kramer. 1994. Detection of Borrelia burgdorferi sensu lato in lesional skin of patients with erythema migrans and acrodermatitits chronica atrophicans by ospA-specific PCR. J. Clin. Microbiol. 32:2980-2988.
47. Nocton, J. J., F. Dressler, R. J. Rutledge, P. N. Rys, D. H. Persing, and A. C. Steere. 1994. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N. Engl. J. Med. 330:229-234.
48. Oksi, J., M. Marjamaki, J. Nikoskelainen, and M. K. Viljanen. 1999. Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann. Med. 31:225-232.
49. Pachner, A. R., E. Delaney, and T. ONeill. 1995. Neuroborreliosis in the nonhuman primate: Borrelia burgdorferi persists in the central nervous system. Ann. Neurol. 38:667-669.
50. Pavia, C., M. A. Inchiosa, and G. P. Wormser. 2002. Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice. Antimicrob. Agents Chemother. 46:132-134.
51. Persing, D. H., B. J. Rutledge, P. N. Rys, D. S. Podzorski, P. D. Mitchell, K. D. Reed, B. Liu, E. Fikrig, and S. E. Malawista. 1994. Target imbalance: disparity of Borrelia burgdorferi genetic material in synovial fluid from Lyme arthritis patients. J. Infect. Dis. 169:668-672.
52. Pfister, H. W., V. Preac-Mursic, B. Wilske, E. Schielke, F. Sorgel, and K. M. Einhaupl. 1991. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J. Infect. Dis. 163:311-318.
53. Philipp, M. T., L. C. Bowers, P. T. Fawcett, M. B. Jacobs, F. T. Liang, A. R. Marques, P. D. Mitchell, J. E. Purcell, M. S. Ratterree, and R. K. Straubinger. 2001. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and humans. J. Infect. Dis. 184:870-878.
54. Preac-Mursic, V., E. Patsouris, B. Wilske, S. Reinhardt, B. Gos, and P. Mehraein. 1990. Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals; comparison with histopathological findings in human Lyme disease. Infection 18:332-341.
55. Preac-Mursic, V., H. W. Pfister, B. Wilske, B. Gross, A. Baumann, and J. Prokop. 1989. Survival of Borrelia burgdorferi in antibiotically treated patients with Lyme borreliosis. Infection 17:355-359.
56. Preac-Mursic, V., B. Wilske, G. Schierz, M. Holmburger, and E. Sub. 1987. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur. J. Clin. Microbiol. 6:424-426.
57. Preac-Mursic, V., B. Wilske, G. Schierz, H. W. Pfister, and K. Einhaupl. 1984. Repeated isolation of spirochetes from the cerebrospinal fluid of a patient with meningoradiculitis Bannwarth. Eur. J. Clin. Microbiol. 3:564-565.
58. Priem, S., G. R. Burmester, T. Kamradt, K. Wolbart, M. G. Rittig, and A. Krause. 1998. Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann. Rheum. Dis. 57:118-121.
59. Roberts, E. D., R. P. Bohm, Jr., F. B. Cogswell, H. N. Lanners, R. C. Lowrie, Jr., L. Povinelli, J. Piesman, and M. T. Philipp. 1995. Chronic Lyme disease in the rhesus monkey. Lab. Invest. 72:146-160.
60. Sartakova, M. L., E. Y. Dobrikova, D. A. Terekhova, R. Devis, J. V. Bugrysheva, O. V. Morozova, H. P. Godfrey, and F. C. Cabello. 2003. Novel antibiotic-resistance markers in pGK12-derived vectors for Borrelia burgdorferi. Gene 303:131-137.
61. Sauve, C., E. Azoulay-Dupuis, P. Moine, C. Darras-Joly, V. Rieux, C. Carbon, and J. P. Bedos. 1996. Efficacies of cefotaxime and ceftriaxone in a mouse model of pneumonia induced by two penicillin- and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2829-2834.
62. Schmidli, J., T. Hunziker, P. Moesli, and U. B. Schaad. 1988. Cultivation of Borrelia burgdorferi from joint fluid three months after treatment of facial palsy due to Lyme borreliosis. J. Infect. Dis. 158:905-906.
63. Schmitz, J. L., R. F. Schell, S. D. Lovrich, S. M. Callister, and J. E. Coe. 1991. Characterization of the protective antibody response to Borrelia burgdorferi in experimentally infected LSH hamsters. Infect. Immun. 59:1916-1921.
64. Schwan, T. G., W. Burgdorfer, M. E. Schrumpf, and R. H. Karstens. 1988. The urinary bladder: a consistent source of Borrelia burgdorferi in experimentally infected white-footed mice (Peromyscus leucopus). J. Clin. Microbiol. 26:893-895.
65. Snydman, D. R., D. P. Schenkein, V. P. Berardi, C. C. Lastavica, and K. M. Pariser. 1986. Borrelia burgdorferi in joint fluid in chronic Lyme arthritis. Ann. Intern. Med. 104:798-800.
66. Sonnesyn, S. W., J. C. Manivel, R. C. Johnson, and J. L. Goodman. 1993. A guinea pig model for Lyme disease. Infect. Immun. 61:4777-4784.
67. Stanek, G., J. Klein, R. Bittner, and D. Glogar. 1990. Isolation of Borrelia burgdorferi from the myocardium of a patient with longstanding cardiomyopathy. N. Engl. J. Med. 322:249-252.
68. Steere, A. C. 2001. Lyme disease. N. Engl. J. Med. 345:115-125.
69. Straubinger, R. K., A. F. Straubinger, B. A. Summers, and R. H. Jacobson. 2000. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: an experimental study. J. Infect. Dis. 181:1069-1081.
70. Straubinger, R. K., B. A. Summers, Y. F. Chang, and M. J. G. Appel. 1997. Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J. Clin. Microbiol. 35:111-116.
71. Strle, F., Y. Cheng, J. Cimperman, V. Maraspin, S. Lotric-Furlan, J. A. Nelson, M. M. Picken, E. Ruzic-Sabljic, and R. N. Picken. 1995. Persistence of Borrelia burgdorferi sensu lato in resolved erythema migrans lesions. Clin. Infect. Dis. 21:380-389.
72. Strle, F., V. Preac-Mursic, J. Cimperman, E. Ruzic, V. Maraspin, and M. Jereb. 1993. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 21:83-88.
73. Terekhova, D., M. L. Sartakova, G. P. Wormser, I. Schwartz, and F. C. Cabello. 2002. Erythromycin resistance in Borrelia burgdorferi. Antimicrob. Agents Chemother. 46:3637-3640.
74. von Stedingk, L. T., I. Olsson, H. S. Hanson, E. Asbrink, and A. Hovmark. 1995. Polymerase chain reaction for detection of Borrelia burgdorferi DNA in skin lesions of early and late Lyme borreliosis. Eur. J. Clin. Microbiol. Infect. Dis. 14:1-5.
75. Wang, E., Y. Bergeron, and M. G. Bergeron. 2005. Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia. J. Antimicrob. Chemother. 55:721-726.
76. Wang, X. G., J. M. Kidder, J. P. Scagliotti, M. S. Klempner, R. Noring, and L. T. Hu. 2004. Analysis of differences in the functional properties of the substrate binding proteins of the Borrelia burgdorferi oligopeptide permease (Opp) operon. J. Bacteriol. 186:51-60.
77. Wang, X. G., B. Lin, J. M. Kidder, S. Telford, and L. T. Hu. 2002. Effects of environmental changes on expression of the oligopeptide permease (opp) genes of Borrelia burgdorferi. J. Bacteriol. 184:6198-6206.
78. Wormser, G. P., R. J. Dattwyler, E. D. Shapiro, J. J. Halperin, A. C. Steere, M. S. Klempner, P. J. Krause, J. S. Bakken, F. Strle, G. Stanek, L. Bockenstedt, D. Fish, J. S. Dumler, and R. B. Nadelman. 2006. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43:1089-1134. (Erratum, 45:941, 2007.)
79. Wormser, G. P., and I. Schwartz. 2009. Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin. Microbiol. Rev. 22:387-395.
80. Yang, X., A. Nguyen, D. Qiu, and B. J. Luft. 2009. In vitro activity of tigecycline against multiple strains of Borrelia burgdorferi. J. Antimicrob. Chemother. 63:709-712.
81. Yrjanainen, H., J. Hyotenen, S. R. Song, J. Oksi, K. Hartiala, and M. K. Viljanen. 2007. Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes in 4 weeks after ceftriaxone treatment in C3H/He mice. J. Infect. Dis. 195:1489-1496.
82. Zeidner, N. S., K. S. Brandt, E. Dadey, M. C. Dolan, C. Happ, and J. Piesman. 2004. Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis. Antimicrob. Agents Chemotherapy 48:2697-2699.